Correction of murine PKU following AAV-mediated intramuscular expression of a complete phenylalanine hydroxylating system

Zhaobing Ding, Cary Harding, Alexandre Rebuffat, Lina Elzaouk, Jon A. Wolff, Beat Thöny

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Phenylketonuria (PKU) caused by phenylalanine hydroxylase (PAH) deficiency leads to toxic accumulation of phenylalanine (Phe). PAH is predominantly expressed in liver and its activity requires a supply of tetrahydrobiopterin (BH4) cofactor, but we propose that expression of a complete Phe hydroxylating system (PAH plus BH4 synthetic enzymes) in skeletal muscle will lead to therapeutic reduction of blood Phe levels in Pahenu2 mice, a model of human PKU. In order to test this hypothesis, we first developed transgenic Pahenu2 mice that lack liver PAH activity but coexpress, in their skeletal muscle, PAH and guanosine triphosphate cyclohydrolase I (GTPCH). The latter is responsible for the committing enzymatic step in BH4 biosynthesis. Despite sufficient muscle enzyme expression, these mice remained hyperphenylalaninemic, thereby suggesting that expression of additional BH4 synthetic enzymes would be necessary. A recombinant triple-cistronic adeno-associated virus-2 (AAV2) pseudotype 1 vector expressing PAH along with GTPCH and 6-pyruvoyltetrahydrobiopterin synthase (PTPS), the next step in BH4 synthesis, was generated. Injection of this vector into the gastrocnemius muscles of Pahenu2 mice led to stable and long-term reduction of blood Phe and reversal of PKU-associated coat hypopigmentation. We propose that muscle-directed gene therapy will be a viable alternative treatment approach to PKU and other inborn errors of metabolism.

Original languageEnglish (US)
Pages (from-to)673-681
Number of pages9
JournalMolecular Therapy
Volume16
Issue number4
DOIs
StatePublished - Apr 2008

Fingerprint

Phenylalanine Hydroxylase
Phenylketonurias
Phenylalanine
Skeletal Muscle
Guanosine Triphosphate
Enzymes
Hypopigmentation
Inborn Errors Metabolism
Muscles
Dependovirus
Poisons
Liver
Genetic Therapy
Transgenic Mice
Injections
Therapeutics

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Correction of murine PKU following AAV-mediated intramuscular expression of a complete phenylalanine hydroxylating system. / Ding, Zhaobing; Harding, Cary; Rebuffat, Alexandre; Elzaouk, Lina; Wolff, Jon A.; Thöny, Beat.

In: Molecular Therapy, Vol. 16, No. 4, 04.2008, p. 673-681.

Research output: Contribution to journalArticle

Ding, Zhaobing ; Harding, Cary ; Rebuffat, Alexandre ; Elzaouk, Lina ; Wolff, Jon A. ; Thöny, Beat. / Correction of murine PKU following AAV-mediated intramuscular expression of a complete phenylalanine hydroxylating system. In: Molecular Therapy. 2008 ; Vol. 16, No. 4. pp. 673-681.
@article{d2c9993359ca4fbebd7503182710ff0e,
title = "Correction of murine PKU following AAV-mediated intramuscular expression of a complete phenylalanine hydroxylating system",
abstract = "Phenylketonuria (PKU) caused by phenylalanine hydroxylase (PAH) deficiency leads to toxic accumulation of phenylalanine (Phe). PAH is predominantly expressed in liver and its activity requires a supply of tetrahydrobiopterin (BH4) cofactor, but we propose that expression of a complete Phe hydroxylating system (PAH plus BH4 synthetic enzymes) in skeletal muscle will lead to therapeutic reduction of blood Phe levels in Pahenu2 mice, a model of human PKU. In order to test this hypothesis, we first developed transgenic Pahenu2 mice that lack liver PAH activity but coexpress, in their skeletal muscle, PAH and guanosine triphosphate cyclohydrolase I (GTPCH). The latter is responsible for the committing enzymatic step in BH4 biosynthesis. Despite sufficient muscle enzyme expression, these mice remained hyperphenylalaninemic, thereby suggesting that expression of additional BH4 synthetic enzymes would be necessary. A recombinant triple-cistronic adeno-associated virus-2 (AAV2) pseudotype 1 vector expressing PAH along with GTPCH and 6-pyruvoyltetrahydrobiopterin synthase (PTPS), the next step in BH4 synthesis, was generated. Injection of this vector into the gastrocnemius muscles of Pahenu2 mice led to stable and long-term reduction of blood Phe and reversal of PKU-associated coat hypopigmentation. We propose that muscle-directed gene therapy will be a viable alternative treatment approach to PKU and other inborn errors of metabolism.",
author = "Zhaobing Ding and Cary Harding and Alexandre Rebuffat and Lina Elzaouk and Wolff, {Jon A.} and Beat Th{\"o}ny",
year = "2008",
month = "4",
doi = "10.1038/mt.2008.17",
language = "English (US)",
volume = "16",
pages = "673--681",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Correction of murine PKU following AAV-mediated intramuscular expression of a complete phenylalanine hydroxylating system

AU - Ding, Zhaobing

AU - Harding, Cary

AU - Rebuffat, Alexandre

AU - Elzaouk, Lina

AU - Wolff, Jon A.

AU - Thöny, Beat

PY - 2008/4

Y1 - 2008/4

N2 - Phenylketonuria (PKU) caused by phenylalanine hydroxylase (PAH) deficiency leads to toxic accumulation of phenylalanine (Phe). PAH is predominantly expressed in liver and its activity requires a supply of tetrahydrobiopterin (BH4) cofactor, but we propose that expression of a complete Phe hydroxylating system (PAH plus BH4 synthetic enzymes) in skeletal muscle will lead to therapeutic reduction of blood Phe levels in Pahenu2 mice, a model of human PKU. In order to test this hypothesis, we first developed transgenic Pahenu2 mice that lack liver PAH activity but coexpress, in their skeletal muscle, PAH and guanosine triphosphate cyclohydrolase I (GTPCH). The latter is responsible for the committing enzymatic step in BH4 biosynthesis. Despite sufficient muscle enzyme expression, these mice remained hyperphenylalaninemic, thereby suggesting that expression of additional BH4 synthetic enzymes would be necessary. A recombinant triple-cistronic adeno-associated virus-2 (AAV2) pseudotype 1 vector expressing PAH along with GTPCH and 6-pyruvoyltetrahydrobiopterin synthase (PTPS), the next step in BH4 synthesis, was generated. Injection of this vector into the gastrocnemius muscles of Pahenu2 mice led to stable and long-term reduction of blood Phe and reversal of PKU-associated coat hypopigmentation. We propose that muscle-directed gene therapy will be a viable alternative treatment approach to PKU and other inborn errors of metabolism.

AB - Phenylketonuria (PKU) caused by phenylalanine hydroxylase (PAH) deficiency leads to toxic accumulation of phenylalanine (Phe). PAH is predominantly expressed in liver and its activity requires a supply of tetrahydrobiopterin (BH4) cofactor, but we propose that expression of a complete Phe hydroxylating system (PAH plus BH4 synthetic enzymes) in skeletal muscle will lead to therapeutic reduction of blood Phe levels in Pahenu2 mice, a model of human PKU. In order to test this hypothesis, we first developed transgenic Pahenu2 mice that lack liver PAH activity but coexpress, in their skeletal muscle, PAH and guanosine triphosphate cyclohydrolase I (GTPCH). The latter is responsible for the committing enzymatic step in BH4 biosynthesis. Despite sufficient muscle enzyme expression, these mice remained hyperphenylalaninemic, thereby suggesting that expression of additional BH4 synthetic enzymes would be necessary. A recombinant triple-cistronic adeno-associated virus-2 (AAV2) pseudotype 1 vector expressing PAH along with GTPCH and 6-pyruvoyltetrahydrobiopterin synthase (PTPS), the next step in BH4 synthesis, was generated. Injection of this vector into the gastrocnemius muscles of Pahenu2 mice led to stable and long-term reduction of blood Phe and reversal of PKU-associated coat hypopigmentation. We propose that muscle-directed gene therapy will be a viable alternative treatment approach to PKU and other inborn errors of metabolism.

UR - http://www.scopus.com/inward/record.url?scp=41149168735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41149168735&partnerID=8YFLogxK

U2 - 10.1038/mt.2008.17

DO - 10.1038/mt.2008.17

M3 - Article

VL - 16

SP - 673

EP - 681

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 4

ER -